| What is given | Topical steroids, tacrolimus, JAK inhibitors, narrowband UVB, excimer, grafting | Bakuchi (psoralen) paste or oil with sun; oral herbal formulations; diet rules; panchakarma | Psoralea and Ammi majus formulations, oral and topical, with sun; diet rules | Highly diluted remedies chosen by symptom picture |
| Mechanism shown | Immune suppression in the patch; follicular pigment cells recruited by light; cells moved by surgery | Psoralen photosensitisation: the PUVA mechanism, unmetered | Psoralen photosensitisation: the PUVA mechanism, unmetered | None demonstrated at the dilutions used |
| Evidence | Randomised trials, national guidelines, the IADVL surgical consensus | Small uncontrolled series; psoralen chemistry well studied | Small uncontrolled series and institutional trials | Case series and open observational studies; no controlled trial showing an effect |
| How improvement is reported | Measured extent (VASI) and photographs at fixed intervals | Usually as a share of patients ‘improved’, without measurement | Usually as a share of patients ‘improved’, without measurement | Case reports |
| Time to a verdict | Three to six months for light and creams; three months for a graft | Months to years; no defined stopping point | Months to years; no defined stopping point | Open-ended |
| Cost pattern | Per session, per procedure; consultation fee fixed | Often monthly courses of formulations; sometimes packages | Often monthly courses of formulations | Monthly |
| Main risk | Steroid thinning if misused; monitoring burden with oral JAK inhibitors | Phototoxic burns and blisters; liver injury reported with oral Psoralea; undeclared steroids in some dispensed preparations | Phototoxic burns; undeclared steroids in some dispensed preparations | Delay while active disease spreads |